Titan Medical Reports Voting Results From Annual and Special Meeting of Shareholders
June 09 2022 - 6:57PM
Titan Medical Inc. (Nasdaq:
TMDI; TSX: TMD),
a medical device company focused on the development and
commercialization of innovative surgical technologies for single
access robotic-assisted surgery (RAS), today announced the voting
results form the company’s Annual and Special Meeting of its
shareholders held on Wednesday June 8, 2022.
All of management’s nominees for election were duly elected as
directors of the company by the shareholders presented or
represented by proxy at the meeting. A total of 54,760,905 of the
111,202,690 common shares outstanding, or 49.24%, were voted at the
meeting. The results of the vote were reported to the meeting by
Computershare, which acted as scrutineer at the meeting and were as
follows:
Directors |
Votes For |
% |
Votes Withheld |
% |
Paul Cataford |
16,268,282 |
75.34 |
5,324,019 |
24.66 |
Anthony J. Giovinazzo |
17,105,583 |
79.22 |
4,486,718 |
20.78 |
Cary G. Vance |
15,885,696 |
73.57 |
5,706,605 |
26.43 |
Heather L. Knight |
19,468,957 |
90.17 |
2,123,344 |
9.83 |
Cathy Steiner |
18,634,425 |
86.30 |
2,957,876 |
13.70 |
The appointment of BDO Canada LLP as independent auditors of the
company was approved by shareholders (with 52,303,729 votes for and
2,456,109 votes withheld) in respect of the motion.
Renewal and Amendment of the company’s share unit plan was
approved by shareholders (with 16,227,277 votes for and 5,338,024
votes withheld) in respect of the motion.
Renewal and Amendment of the company’s deferred share unit plan
was approved by shareholders (with 16,356,916 votes for and
5,208,385 votes withheld) in respect of the motion.
Approval of adoption of an employee share purchase plan was
approved by shareholders (with 17,346,237 votes for and 4,219,064
votes withheld) in respect of the motion.
About Titan Medical
Titan Medical Inc. (Nasdaq: TMDI; TSX: TMD), a medical device
company headquartered in Toronto, Ontario and with operations in
Chapel Hill, North Carolina, is focused on enhancing robotic
assisted surgery using innovative technology through a single
access point. The Enos™ robotic single access surgical system is
being developed with an ergonomic focus to provide a surgical
experience that imitates real-life movements that surgeons demand
and includes multi-articulating instruments designed to allow
surgeons an increased range of motion in a confined space, with
dexterity and the ability to exert the forces necessary to complete
common surgical tasks. With the Enos system, Titan intends to
initially pursue gynecologic surgical indications.
Enos™ is a trademark of Titan Medical Inc.
For more information,
visit www.titanmedicalinc.com and
follow @TitanMedical on Twitter and LinkedIn.
Forward-Looking Statements
This news release contains “forward-looking statements” within
the meaning of applicable Canadian and U.S. securities laws, which
reflect the current expectations of management of the company’s
future growth, results of operations, performance, and business
prospects and opportunities. Wherever possible, words such as
“may”, “would”, “could”, “will”, “anticipate”, “believe”, “plan”,
“expect”, “intend”, “estimate”, “potential for” and similar
expressions have been used to identify these forward-looking
statements, including, without limitation, references to: the
company’s focus on the design and development of surgical
technologies for robotic single access surgery; the Enos system
providing a surgical experience that imitates real-life movements;
and the company’s intention to initially pursue gynecologic
surgical indications with the Enos system. These statements reflect
management’s current beliefs and are based on information currently
available to management. Forward-looking statements involve
significant risks, uncertainties and assumptions. Many factors
could cause the company’s actual results, performance or
achievements to be materially different from any future results,
performance or achievements that may be expressed or implied by
such forward-looking statements, including, without limitation,
those listed in the “Risk Factors” section of the company’s Annual
Report for the fiscal year ended December 31, 2021, which may be
viewed at www.sedar.com and at www.sec.gov. Should one or more of
these risks or uncertainties materialize, or should assumptions
underlying the forward-looking statements prove incorrect, actual
results, performance, or achievements may vary materially from
those expressed or implied by the forward-looking statements
contained in this news release. These factors should be considered
carefully, and prospective investors should not place undue
reliance on the forward-looking statements. Although the
forward-looking statements contained in the news release are based
upon what management currently believes to be reasonable
assumptions, the company cannot assure prospective investors that
actual results, performance or achievements will be consistent with
these forward-looking statements. Except as required by law, the
company expressly disclaims any intention or obligation to update
or revise any forward-looking statements whether as a result of new
information, future events or otherwise.
ContactKristen GalfettiVice President, Investor
Relations & Corporate
Communications+1-781-869-2553investors@titanmedicalinc.com
###
Titan Medical (NASDAQ:TMDI)
Historical Stock Chart
From Mar 2024 to Apr 2024
Titan Medical (NASDAQ:TMDI)
Historical Stock Chart
From Apr 2023 to Apr 2024